Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesTeneligliptin in management of type 2 diabetes mellitusAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitusEfficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.Emerging gliptins for type 2 diabetes.Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialTeneligliptin: a review in type 2 diabetes.Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.Efficacy and safety of teneligliptin.Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study.Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling
P2860
Q24628948-802C95B1-4797-43ED-A624-1F334CB809C4Q26738356-C0370B6A-D81D-4DB6-AF5E-18E0F1547F33Q26785454-34D8B372-C788-42C9-AECD-841EBFDC8312Q30240823-CD956110-6909-4D98-994B-0860FF85C270Q33607742-C1532B6D-5DF8-4B80-9256-CA92BF8C69E3Q33835558-E243882E-2CFF-4AC9-B551-9AAC98824B5FQ34347884-4052636C-99A7-447B-8552-53F938988357Q35976493-ED70AC9B-4CDD-4BBD-8010-D576583C8079Q36031120-2D750804-8605-4012-937D-422A54CA9DFDQ37348976-2324C9FA-64ED-4CF2-B015-B29C786EAACEQ38609598-4069B7A4-86EA-4CD6-B745-515213ACE4FBQ38716033-5167B928-5010-48DF-B3AB-E50EB246BF22Q39161794-11BE242A-5939-4396-A948-D8C19F915036Q39489506-4DB3E637-8C01-4BB1-877B-D6124172185EQ40753056-F9C42B1E-93FF-40FA-9383-A98CABDCF342Q41090670-060D5EC3-3208-48EF-BEE8-41FAF91D9587Q42330154-44BBD933-1089-4F9E-A25B-8C9E38094396Q44067944-0904056A-4CB6-4606-89A9-81F2FD8F89A0Q45327154-E8E72FEA-E0DD-4C0D-99A2-6DF1903EEB58Q46231385-5904D0E9-E457-43FB-BF30-26D091F5B298Q46982494-45D5E891-0C26-44B9-8DCC-2386AE7037BBQ47148933-335DB4E3-E431-4D6D-A32C-003547044B80Q48031376-9B5D8918-3B06-4ADD-AD87-0979CDDC66E0Q50050575-77EC770D-BAD8-415F-B10C-CDF734296D48Q51245374-940049B8-D8E2-48BE-9A9C-81E0A0FDD41DQ51311444-D8262208-4B43-40A6-A4A0-18B0A8C2A6DEQ51343741-8DDEA9ED-9D2A-4587-B222-7A38AF63CE7CQ52594764-9A6ACB76-1A0D-4DCB-B7B5-BB97A96B3AD2Q55340870-1563717B-A422-4977-9289-1CC83125470AQ55401867-ABDAD66A-23C2-4D46-8F5F-7E8A8E76643DQ59152982-5A18A34D-9AA0-40B1-A042-A39B086BF630
P2860
Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Effects of once-daily teneligl ...... ind, placebo-controlled trial.
@en
Effects of once-daily teneligl ...... ind, placebo-controlled trial.
@nl
type
label
Effects of once-daily teneligl ...... ind, placebo-controlled trial.
@en
Effects of once-daily teneligl ...... ind, placebo-controlled trial.
@nl
prefLabel
Effects of once-daily teneligl ...... ind, placebo-controlled trial.
@en
Effects of once-daily teneligl ...... ind, placebo-controlled trial.
@nl
P2093
P1476
Effects of once-daily teneligl ...... ind, placebo-controlled trial.
@en
P2093
P304
P356
10.1111/J.1463-1326.2012.01662.X
P577
2012-07-29T00:00:00Z